The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
Manasvi Gupta,1 Shiavax Rao,2 Gaurav Manek,1 Gregg C Fonarow,3 Raktim K Ghosh4 1Department of Internal Medicine, University of Connecticut, Hartford, CT, USA; 2Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; 3Department of Medicine, Ronald Reagan UCLA Medical Center, Los...
Guardado en:
Autores principales: | Gupta M, Rao S, Manek G, Fonarow GC, Ghosh RK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/69369d87bd334ec281d0b61a674f8fe7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Jadwiga Nessler
Publicado: (2021) -
Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain
por: Carlos Escobar, et al.
Publicado: (2021) -
Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome
por: Hwee-Yeong Ng, et al.
Publicado: (2021) -
Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016) -
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou I, et al.
Publicado: (2019)